AD-303A not checked

Moogene Medi Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Topical AD-303A applied to the scalp according to the study protocol.”In the company’s words, NCT07490327 on ClinicalTrials.gov
Tested for
Androgenetic Alopecia
Main trialPhase 1/2
“This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.”In the company’s words, NCT07490327 on ClinicalTrials.gov

Other drugs for Androgenetic Alopecia

All 36 drugs for Androgenetic Alopecia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting Sep 2026 Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AD-303A

Following is part of Solo: you see every change to AD-303A the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in